Abelacimab for Prevention of Venous Thromboembolism. Reply
N Engl J Med
.
2021 Nov 4;385(19):1822-1823.
doi: 10.1056/NEJMc2114895.
Authors
Jeffrey I Weitz
1
,
Gary E Raskob
2
,
B Alexander Yi
3
Affiliations
1
McMaster University, Hamilton, ON, Canada weitzj@taari.ca.
2
University of Oklahoma Health Sciences Center, Oklahoma City, OK.
3
Anthos Therapeutics, Cambridge, MA.
PMID:
34731547
DOI:
10.1056/NEJMc2114895
No abstract available
Publication types
Letter
Comment
MeSH terms
Anticoagulants / adverse effects
Humans
Risk Factors
Venous Thromboembolism* / prevention & control
Substances
Anticoagulants